Biotech | January 22, 2022
Positive top-line results for bimekizumab in second phase 3 psoriatic arthritis study
UCB plans to submit regulatory applications in Q3 2022
UCB plans to submit regulatory applications in Q3 2022
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
It has also been granted permission to conduct trials for booster dose
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
_256_384.jpg)
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
Subscribe To Our Newsletter & Stay Updated
